SLC16A3: A Protein That Interacts with Metformin and Has Potential as A Drug Target

Target Name: SLC16A3

NCBI ID: G9123

SLC16A3

SLC16A3: A Protein That Interacts with Metformin and Has Potential as A Drug Target

SLC16A3 (MCT 3) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the sulfate transporter family 16 (SLC16 family), which is responsible for transporting a variety of molecules across cell membranes. One of the unique aspects of SLC16A3 is its ability to interact with the drug metformin, which is commonly used to treat type 2 diabetes.

SLC16A3 has been identified as a potential drug target for the treatment of various diseases, including diabetes, heart disease, and neurodegenerative disorders. Its unique ability to interact with metformin has led to the investigation of its potential as a drug for the treatment of diabetes in particular.

In addition to its potential as a drug target, SLC16A3 has also been shown to be a valuable biomarker for the diagnosis and monitoring of various diseases. Its expression has been observed in a variety of diseases, including diabetes, heart disease, and neurodegenerative disorders, which suggests that it may be a useful diagnostic tool for these conditions.

One of the main challenges in studying SLC16A3 as a potential drug target is its complex structure and the difficulty of predicting how it will interact with small molecules. However, recent studies have provided some insight into the mechanism of SLC16A3's interaction with metformin.

SLC16A3 is a 22kDa protein that consists of an N-terminus, a catalytic C-terminus, and a C-terminal region that is responsible for its interaction with small molecules. The N-terminus of SLC16A3 contains a putative transmembrane segment (TMS) that is involved in the regulation of its trafficking and localization to different cellular compartments. The TMS region is thought to play a role in SLC16A3's ability to interact with metformin, as metformin has been shown to interact with the TMS region and disrupt its transmembrane activity.

The catalytic C-terminus of SLC16A3 contains a putative nucleotide-binding site (NBS) that is responsible for catalyzing the transfer of nucleotides across the membrane. The NBS is thought to play a key role in SLC16A3's interaction with metformin, as metformin has been shown to inhibit the activity of SLC16A3's NBS and disrupt its nucleotide-binding activity.

The C-terminal region of SLC16A3 is responsible for its interaction with small molecules and has been shown to play a key role in its function. The C-terminus of SLC16A3 contains a putative hormone-binding site (HBS) that is thought to play a role in SLC16A3's interaction with metformin. The HBS is known to be involved in the regulation of various physiological processes, including metabolism and insulin sensitivity, and is thought to be involved in the metformin-SLC16A3 interaction.

In conclusion, SLC16A3 is a unique protein that has been shown to interact with the drug metformin and has the potential as a drug target for the treatment of various diseases. Its complex structure and the difficulty of predicting its interaction with small molecules make it challenging to study, but recent studies have provided some insight into its mechanism of interaction with metformin. Further research is needed to fully understand the potential of SLC16A3 as a drug target and to develop effective treatments for diabetes and other diseases.

Protein Name: Solute Carrier Family 16 Member 3

Functions: Proton-dependent transporter of monocarboxylates such as L-lactate and pyruvate (PubMed:11101640, PubMed:23935841, PubMed:31719150). Plays a predominant role in L-lactate efflux from highly glycolytic cells (By similarity)

The "SLC16A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC16A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets